Machine Learning From Fetal Flow Waveforms to Predict Adverse Perinatal Outcomes

January 6, 2018 updated by: Zahra Hoodbhoy, Aga Khan University

The aim of this study is to get a proof of concept for using a computational model of fetal haemodynamics, combined with machine learning based on Doppler patterns of the fetal cardiovascular, cerebral and placental flows, to identify those at increased risk of adverse perinatal outcomes such as stillbirth, perinatal mortality and other neonatal morbidities.

We will also compare the sensitivity and specificity of UmbiFlow device with the machine learning model in predicting adverse perinatal outcomes

Study Overview

Status

Unknown

Detailed Description

Pakistan is one of the countries where stillbirth rate (43/1000 total births) and neonatal mortality rate (55/1000 live births) are among the highest in the world. The figures for perinatal mortality remained unchanged between Pakistan Demographic and Health Survey (PDHS) 1990-91 and PDHS 2012-13. It is hence important to evaluate new techniques to identify high-risk pregnant women who can then subsequently receive personalized care to improve perinatal outcomes. Fetal blood flow waveforms assessed via Doppler ultrasound to indicate wellbeing of the fetus have been in practice for nearly four decades. Abnormal blood flow patterns in the fetal circulation detected by Doppler ultrasound may indicate poor fetal prognosis. These tracings will then be incorporated in a computational model and combined with machine learning, will be used to predict adverse perinatal outcomes.

This will be a prospective one group cohort study for a period of twelve months which will be based in Ibrahim Hyderi, a peri-urban settlement of approximately 70,000 on the south east of Karachi. The sample size for this study has been calculated based on the outcomes of the pregnancy and was estimated to be 525 pregnant women.

Recruitment - Household surveillance will be done by community health workers (CHWs) in the catchment area in a sequential manner to identify pregnant women. Eligible women between 22-34 weeks of gestation on last menstrual period (LMP) will then be explained regarding the purpose of the study and invited for an ultrasound scan.

First and enrollment visit - The first visit window for the ultrasound scan will be between 22-26 weeks of gestation. This window is selected because pregnancies at risk may be better identified and also visualization of fetal cardiac flow is possible. Based on the rigorous surveillance, we anticipate that most women will be in this window. The following information will be collected:

  • Socio-demographic information
  • Medical history, including exposure to tobacco, gravidity, parity, past obstetric history (including number of miscarriages, stillbirths or neonatal deaths) and comorbid conditions (pre-eclampsia, diabetes mellitus)
  • Maternal anthropometry (height, weight and mid-upper arm circumference)
  • Maternal blood pressure
  • Hemoglobin of the mother
  • Symphysiofundal height will be measured
  • Standard obstetric Doppler evaluation including the four primary ultrasound measures of fetal growth-head circumference, biparietal diameter, abdominal circumference, and femur length is routinely performed for all pregnant women presenting at the center. These parameters will be used to estimate fetal weight (automatically calculated by the machine).
  • Focused Fetal Doppler Echocardiography - These would include transabdominal measurements of the Doppler velocity of the umbilical artery, the middle cerebral artery (MCA), ductus arteriosus, fetal aortic isthmus (AoI) and left and right ventricular outflow tracts
  • UmbiFlow - Umbilical artery continuous wave Doppler image will also be obtained on these women. The device will generate graphs for the flow pattern and calculate the resistance index for the flow.

Second visit - The second visit window of ultrasound scan will be between 30-34 weeks of gestation. This will be applicable for all women who have had their first scan during 22-26 weeks of gestation as well as newly enrolled women during 30-34 weeks of gestational age. Cardiotocography (CTG) will be performed for all recruited women during the second visit followed by the Doppler examination. The same procedures as described in the first visit will be done.

Follow up - We will obtain contact information (phone number) from all enrolled women. A trained research midwife will be responsible for making phone calls, as well as performing household visits at pre-specified intervals for immediate and early identification of the pregnancy outcome. A team of CHWs will perform home visits to the baby at post-natal day 1 and 6 and questions related to delayed cry, neonatal sepsis and hospital course (if any) will be collected and the weight and length of the baby will be recorded.

Verbal autopsy - The VA team will visit the family after the grieving period (at least 14 days after the death). VA will be performed using a structured tool (http://www.who.int/healthinfo/statistics/WHO_VA_2012_RC1_Instrument.pdf ).

Study Type

Observational

Enrollment (Anticipated)

525

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • ADULT
  • OLDER_ADULT
  • CHILD

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Female

Sampling Method

Non-Probability Sample

Study Population

Pregnant women between 22-34 weeks who reside in Ibrahim Hyderi Goth which is a peri-urban settlement of approximately 70,000 on the south east of Karachi. It is one of the seven union councils in Bin Qasim town which has a population of one million.

Description

Inclusion Criteria:

  • Pregnant woman coming to the ultrasound clinic between 22-34 weeks of gestation.
  • Written informed consent
  • Resident of the study area

Exclusion Criteria:

  • Multiple gestation
  • Known congenital anomaly in the fetus or newborn
  • Refusal for the ultrasound
  • Poor echocardiographic images for Doppler acquisition

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Stillbirth
Time Frame: At birth
Baby born with no signs of life at or after 28 weeks of gestation
At birth
Early neonatal mortality
Time Frame: Within the first 7 days of life
Death of a baby within the first 7 days of life
Within the first 7 days of life

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
IUGR
Time Frame: At birth
Fetal weight that is below the 10th percentile for gestational age as determined through an ultrasound
At birth
Prematurity
Time Frame: At birth
Birth of a fetus at < 37 weeks of gestation
At birth
Birth asphyxia
Time Frame: At birth
Delayed cry after at least 1 minute of life
At birth
Neonatal sepsis
Time Frame: Within the first 7 days of life
Any 1 of the following danger signs: fever > 38 of < 35.5 C, convulsions, lethargy, poor feeding, chest in drawing and tachypnea (respiratory rate > 60/min)
Within the first 7 days of life
Low Birth Weight
Time Frame: At birth
Birth weight < 2.5 kg
At birth

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ANTICIPATED)

February 1, 2018

Primary Completion (ANTICIPATED)

September 1, 2018

Study Completion (ANTICIPATED)

December 1, 2018

Study Registration Dates

First Submitted

January 6, 2018

First Submitted That Met QC Criteria

January 6, 2018

First Posted (ACTUAL)

January 12, 2018

Study Record Updates

Last Update Posted (ACTUAL)

January 12, 2018

Last Update Submitted That Met QC Criteria

January 6, 2018

Last Verified

January 1, 2018

More Information

Terms related to this study

Other Study ID Numbers

  • 4872-Ped-ERC-17

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Perinatal Mortality

Subscribe